- Home
- SYNX vs NCNA Comparison
SYNX vs NCNA Comparison
Compare SYNX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYNX | NCNA |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.5M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SYNX | NCNA |
|---|---|---|
| Price | $0.98 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 38.9K | 23.2K |
| Earning Date | 08-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.21 |
| 52 Week High | $1.95 | $7.01 |
Technical Indicators
Market Signals| Indicator | SYNX | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 37.96 |
| Support Level | $0.94 | $1.21 |
| Resistance Level | $1.09 | $1.40 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 80.01 | 56.13 |
Price Performance
Historical ComparisonAbout SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.